ALPN News and Press, Alpine Immune Sciences Inc. From 05/30/22

Studies suggest that index rebalancing anomalies generate excess risk-adjusted returns caused by stock index funds and institutional investors that benchmark the indexes. Four years of research including the most robust 2021 study come to a close on the annual June rebalancing and som...

- ALPN-303 Novel Preclinical Data and Preliminary Phase 1 Data at EULAR – - Davoceticept (ALPN-202) Monotherapy Update and Trials in Progress Poster for Pembrolizumab Combination Study at ASCO - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinic...

Alpine Immune Sciences (NASDAQ:ALPN) said on Tuesday the U.S. Food and drug Administration had removed the partial clinical hold placed on trial evaluating its drug candidate davoceticept in combination with Merck's (MRK) Keytruda (pembrolizumab) in adults with advanced malignancies. The...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical ...

Alpine Immune Sciences press release (NASDAQ:ALPN): Q1 GAAP EPS of -$0.25. Collaboration Revenue of $13.63M. As of March 31, 2022, the company had cash, cash equivalents, and investments totaling $219.1 million. Net cash provided by operating activities for the quarter ended March 31, 2022 wa...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ended March...

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor con...

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure thr...

- In dose escalation across a range of dose regimens, tumor volume reduction was observed in 23% of evaluable participants despite heavily pretreated, advanced solid malignancies - - Monotherapy expansion cohorts with multiple tumor types are planned - Alpine Immune ...

- AACR Investor Event time change to 6:30 p.m. ET - - 21st Annual Needham Virtual Healthcare Conference Presentation April 13 th at 1:30 p.m. ET - Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing inno...